We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+32.82%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.14B
AUM Growth
+$551M
Cap. Flow
+$421M
Cap. Flow %
37.05%
Top 10 Hldgs %
39.86%
Holding
141
New
51
Increased
36
Reduced
11
Closed
41

Top Buys

Rank Stock Value
1
VRAY
ViewRay, Inc.
VRAY
+$18.2M
2
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$10.6M
3
IMDX
Insight Molecular Diagnostics
IMDX
+$10.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.48M
5
SRACU
Stable Road Acquisition Corp. Unit
SRACU
+$4.41M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$11.1M
2
GILD icon
Gilead Sciences
GILD
+$9.51M
3
SNN icon
Smith & Nephew
SNN
+$8.66M
4
BAX icon
Baxter International
BAX
+$4.96M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 26.48%
2 Industrials 0.92%
3 Consumer Staples 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRFS
26
Grifois
GRFS
$5.47B
$13.5M 1.19%
578,620
+82,419
+17% +$1.8M
AGN
27
DELISTED
Allergan plc
AGN
$13.3M 1.17%
69,750
+2,641
+4% +$476K
INOV
28
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
$13.3M 1.17%
708,470
+633,470
+845% +$10.6M
ICUI icon
29
CALL
ICU Medical
ICUI
$4.55B
$13.3M 1.17%
71,000
+43,500
+158% +$7.49M
IMDX
30
Insight Molecular Diagnostics
IMDX
$147M
$12.8M 1.13%
+284,829
New +$10.3M
INSP icon
31
CALL
Inspire Medical Systems
INSP
$1.74B
$12.1M 1.06%
163,000
-112,000
-41% -$7.2M
IVC
32
DELISTED
Invacare Corporation
IVC
$12.1M 1.06%
1,338,493
+518,619
+63% +$4.36M
DXCM icon
33
DexCom
DXCM
$33.6B
$12M 1.06%
220,328
+40,328
+22% +$1.91M
ABT icon
34
PUT
Abbott
ABT
$190B
$11.9M 1.05%
+137,000
New +$11.5M
STAA icon
35
PUT
STAAR Surgical
STAA
$1.27B
$11.5M 1.01%
+327,000
New +$10.8M
KIDS icon
36
OrthoPediatrics
KIDS
$620M
$11.4M 1.01%
243,392
+70,892
+41% +$2.75M
QGEN icon
37
PUT
Qiagen
QGEN
$8.92B
$11.1M 0.97%
+308,379
New +$11.5M
NVRO
38
CALL
DELISTED
NEVRO CORP.
NVRO
$10.8M 0.95%
+92,000
New +$9.11M
CSII
39
PUT
DELISTED
Cardiovascular Systems, Inc.
CSII
$10.6M 0.93%
+218,000
New +$9.93M
RCM
40
DELISTED
R1 RCM Inc. Common Stock
RCM
$10.5M 0.92%
809,610
+52,471
+7% +$599K
QTNT
41
DELISTED
Quotient Limited Ordinary Shares
QTNT
$10.4M 0.91%
27,260
+13,133
+93% +$4.35M
ZBH icon
42
CALL
Zimmer Biomet
ZBH
$18.6B
$9.88M 0.87%
67,980
-35,020
-34% -$4.83M
ALXN
43
DELISTED
Alexion Pharmaceuticals
ALXN
$9.43M 0.83%
87,190
+34,690
+66% +$3.71M
RVTY icon
44
PUT
Revvity
RVTY
$12.9B
$9.13M 0.8%
+94,000
New +$8.39M
DVA icon
45
PUT
DaVita
DVA
$11.6B
$8.4M 0.74%
+112,000
New +$7.43M
BCRX icon
46
BioCryst Pharmaceuticals
BCRX
$2.68B
$7.52M 0.66%
+2,179,950
New +$5.48M
GKOS icon
47
PUT
Glaukos
GKOS
$10.7B
$7.19M 0.63%
+132,000
New +$8.03M
SDC
48
PUT
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
$7.17M 0.63%
+820,000
New +$8.2M
TXG icon
49
10x Genomics
TXG
$7.66B
$6.66M 0.59%
87,340
-2,660
-3% -$160K
OMCL icon
50
PUT
Omnicell
OMCL
$1.69B
$6.46M 0.57%
+79,000
New +$6.06M
1
2
3 4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2019 Portfolio in Review

As of Q4 2019, Pura Vida Investments held 141 positions worth $1.14B, up 94% from $585M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Pura Vida Investments deployed $421M of net new capital in Q4 2019, opening 51 new positions and adding to 36 existing holdings. Its largest new stake was Insight Molecular Diagnostics: 284,829 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 40% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Establishment Labs, an estimated $1.39M trimmed.

  • Pura Vida Investments's largest Q4 2019 buy was Insight Molecular Diagnostics: 284,829 shares worth $12.8M.
  • Pura Vida Investments added most to ViewRay, Inc. in Q4 2019, an estimated $18.2M increase.
  • Pura Vida Investments's biggest Q4 2019 reduction was Establishment Labs, cutting an estimated $1.39M.
  • Pura Vida Investments fully exited Regeneron Pharmaceuticals in Q4 2019, selling an estimated $11.1M.
  • Pura Vida Investments's ten largest holdings make up 40% of its $1.14B portfolio in Q4 2019.
  • Pura Vida Investments opened 51 new positions and closed 41 in Q4 2019.
  • Pura Vida Investments's portfolio value rose 94% quarter-over-quarter to $1.14B.

Based on Pura Vida Investments's 13F filing for Q4 2019, filed 14 Feb 2020.